Skip to main content
Year archive

BerGenBio — 2019 filings

All 81 regulatory filings released by BerGenBio (BGBIO) in 2019, sourced directly from the official regulator.

81 Filings
2019 Period
2019 filings (81)
Filing Released Lang
Financial calendar
Report Publication Announcement
2019-12-12 English
BerGenBio presents preliminary clinical data from Phase II combination trial of bemcentinib and LDAC in elderly AML patients at ASH 2019
Regulatory Filings
2019-12-09 English
BerGenBio presents preliminary clinical data from Phase II combination trial of bemcentinib and LDAC in elderly AML patients at ASH 2019
Earnings Release Q4 2019
2019-12-09 English
BerGenBio ASA: Results for the third quarter  2019
Interim / Quarterly Report Q3 2019
2019-11-19 English
BerGenBio ASA: Results for the third quarter  2019
Earnings Release Q3 2019
2019-11-19 English
BerGenBio ASA: Results for the third quarter  2019
Earnings Release Q3 2019
2019-11-19 English
BerGenBio presents updated phase 2 NSCLC clinical and translational data for bemcentinib in combination with KEYTRUDA®
Earnings Release Q4 2019
2019-11-08 English
BerGenBio presents updated phase 2 NSCLC clinical and translational data for bemcentinib in combination with KEYTRUDA®
Earnings Release Q4 2019
2019-11-08 English
BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019
Regulatory Filings
2019-11-07 English
BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019
Regulatory Filings
2019-11-07 English
BERGENBIO ASA: Invitation to third quarter 2019 results presentation and webcast
Report Publication Announcement
2019-11-07 Norwegian
BERGENBIO ASA: Invitation to third quarter 2019 results presentation and webcast
Report Publication Announcement
2019-11-07 English
BERGENBIO'S BEMCENTINIB MEETS PRIMARY ENDPOINT IN FIRST COHORT OF PHASE 2 NSCLC STUDY IN COMBINATION WITH KEYTRUDA®
Earnings Release Q4 2019
2019-11-06 English
BERGENBIO'S BEMCENTINIB MEETS PRIMARY ENDPOINT IN FIRST COHORT OF PHASE 2 NSCLC STUDY IN COMBINATION WITH KEYTRUDA®
Regulatory Filings
2019-11-06 English
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Regulatory Filings
2019-10-22 English
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Regulatory Filings
2019-10-22 English
BerGenBio to Present clinical data from Phase II trial with selective AXL inhibitor at 34th Annual SITC Meeting
Regulatory Filings
2019-10-02 English
BerGenBio to Present clinical data from Phase II trial with selective AXL inhibitor at 34th Annual SITC Meeting
Report Publication Announcement
2019-10-02 English
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Regulatory Filings
2019-09-27 English
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Regulatory Filings
2019-09-27 English
BerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference
Report Publication Announcement
2019-09-10 English
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer
Regulatory Filings
2019-09-08 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2019-09-03 English
BerGenBio ASA: Primary insider notification
Director's Dealing
2019-09-02 English
BerGenBio ASA: Increase of share capital, exercise of share options and primary insider notification
Share Issue/Capital Change
2019-08-28 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Interim / Quarterly Report H1 2019
2019-08-19 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Earnings Release Q2 2019
2019-08-19 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Earnings Release H1 2019
2019-08-19 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Earnings Release H1 2019
2019-08-19 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Earnings Release H1 2019
2019-08-19 English
BerGenBio ASA: Results for the Second Quarter and First Half 2019
Earnings Release H1 2019
2019-08-19 English
BERGENBIO ASA: INVITATION TO SECOND QUARTER AND HALF YEAR 2019 RESULTS PRESENTATION AND WEBCAST
Report Publication Announcement
2019-08-08 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2019-07-01 English
BerGenBio ASA: Exercise of share options and increase of share capital
Share Issue/Capital Change
2019-06-28 English
Financial calendar
Report Publication Announcement
2019-06-24 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2019-06-21 English
BerGenBio ASA: Primary Insider notification
Director's Dealing
2019-06-20 English
BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy
Regulatory Filings
2019-06-14 English
BerGenBio ASA - Successfully Completed Private Placement
Capital/Financing Update
2019-06-13 English
BerGenBio ASA: Contemplated Private Placement
Capital/Financing Update
2019-06-13 English
BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019
Earnings Release Q2 2019
2019-06-03 English
BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in pts with advanced NSCLC at ASCO 2019
Earnings Release Q2 2019
2019-06-02 English
BerGenBio ASA: Invitation to ASCO Update Call
Call Transcript
2019-05-31 English
BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
Investor Presentation
2019-05-15 English
BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC
Regulatory Filings
2019-05-08 English
BerGenBio ASA: Results for the First Quarter 2019
Interim / Quarterly Report Q1 2019
2019-05-08 English
BerGenBio ASA: Results for the First Quarter 2019
Earnings Release Q1 2019
2019-05-08 English
BerGenBio ASA: Results for the First Quarter 2019
Earnings Release Q1 2019
2019-05-08 English
BerGenBio ASA: Invitation to First Quarter Presentation and Webcast
Report Publication Announcement
2019-04-24 English
BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
Report Publication Announcement
2019-04-23 English
BerGenBio ASA: Share options to primary insiders
Remuneration Information
2019-04-23 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2019-04-15 English
BerGenBio ASA: Exercise of share options and increase of share capital
Share Issue/Capital Change
2019-04-12 English
BerGenBio ASA (BGBIO): Primary Insider notification
Director's Dealing
2019-04-11 English
BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference
Regulatory Filings
2019-04-09 English
BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy
Regulatory Filings
2019-04-02 English
BerGenBio: Preclinical data presented at AACR reinforces bemcentinib's potential to reverse tumour immunosuppression and therapy resistance
Regulatory Filings
2019-04-02 English
BerGenBio: Bemcentinib in combination with low-dose chemotherapy achieves efficacy endpoint in AML patients
Regulatory Filings
2019-04-01 English
BerGenBio ASA ("BerGenBio" or "the Company") announces key appointments to executive team and Board to prepare organisation for next phase of development
Board/Management Information
2019-03-13 English
BerGenBio ASA: Annual general meeting
AGM Information
2019-03-13 Norwegian
BerGenBio ASA: Annual general meeting
AGM Information
2019-03-13 English
BerGenBio ASA: Arbitration with Rigel Pharmaceuticals, Inc resolved
Legal Proceedings Report
2019-02-28 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2019-02-20 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2019-02-20 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2019-02-20 English
BerGenBio ASA publishes Annual Report for 2018
Annual Report FY 2018
2019-02-20 Norwegian
BerGenBio ASA publishes Annual Report for 2018
Report Publication Announcement
2019-02-20 Norwegian
BerGenBio ASA publishes Annual Report for 2018
Report Publication Announcement
2019-02-20 English
BerGenBio ASA: Primary Insider notification
Major Shareholding Notification
2019-02-19 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2019-02-18 English
BerGenBio ASA: Exercise of share options and increase of capital
Share Issue/Capital Change
2019-02-14 English
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
Interim / Quarterly Report Q4 2018
2019-02-12 English
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
Investor Presentation
2019-02-12 English
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
Earnings Release Q4 2018
2019-02-12 English
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
Earnings Release FY 2018
2019-02-12 English
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast
Report Publication Announcement
2019-02-05 English
BerGenBio announces the allocation of R&D grant of up to NOK 12m awarded by Research Council of Norway
Regulatory Filings
2019-02-04 English
BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AXL ADC, in patients with advanced solid tumours
Regulatory Filings
2019-01-21 English
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149
Regulatory Filings
2019-01-09 English
BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco
Regulatory Filings
2019-01-08 English
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS
Regulatory Filings
2019-01-04 English